17,261 trials
Postoperative Nausea and Vomiting
Primary: Percentage of Participants With Complete Control — 25.0; 18.0 percentage of participants — p=0.4010
Hematologic Malignancy
Primary: Day +180 Rate of Grade II-IV Acute GVHD — 22 Participants
Breast Neoplasms
Primary: Progression Free Survival (PFS) — 6.18; 4.93 Months — p=0.0372
Warts · Human Papilloma Virus
Primary: Number of Participants With Complete Resolution of Primary Injected Wart — 19 Participants
Respiratory Disorders
Primary: Rate of Moderate and Severe AECOPD (Any Cause)-Analysis (87% Confidence Interval [CI]), Post-dose 2 and Lasting for 1 Year — 1.22; 1.17 exacerbations per person-year…
Psoriasis
Primary: Percent Change From Baseline in Target Plaque Severity Score (TPSS) at Week 4 — -53.97; -41.01; -24.26; -17.24 percent change
Diabetes · Diabetes Mellitus, Type 1
Primary: Area Under the Concentration-time Curve (AUC) 0-4h of Mixed Meal Tolerance Test (MMTT) Stimulated C-peptide at Week 54 Relative to Baseline — 0.934; 0.783; 0.709; 0.660…
HIV Infections
Primary: Number of Participants Reporting Local Reactogenicity Signs and Symptoms During the Vaccine Regimen — 16; 18; 16; 7 Participants
Myocardial Ischemia
Primary: Number of Angina Episodes Per Week at 6 and 12 Months — 6.8; 8.3; 10.9; 6.3 angina episodes/week — p=0.020
Diabetes Mellitus
Primary: Change From Baseline in 4-hour Mixed Meal Tolerance Test (MMTT)-Stimulated C-peptide Area Under the Curve (AUC) at Week 52 — -0.2863; -0.3895; -0.2670 pmol*hr/mL
Coronary Microvascular Dysfunction
Primary: Change From Baseline in Coronary Flow Reserve — 0.62 ratio
Muscular Atrophy, Spinal
Primary: Part 1: Selected Part 2 Dose of Risdiplam — 0.2 mg/kg
Diabetes Mellitus, Type 2
Primary: Percentage of Time in Target Range (TIR) 3.9-10.0 Millimoles Per Liter (mmol/L) (70-180 Milligrams Per Deciliter (mg/dL) Measured Using CGM (Continuous Glucose…
Autosomal Dominant Osteopetrosis Type 2
Primary: Changes in Bone Resorption Markers From Baseline to 14 Weeks. — 2.2; -2.1 percentage of change
Myasthenia Gravis
Primary: Number of Patients With Treatment Emergent Adverse Events (TEAES) and Treatment Emergent Serious Adverse Events (SAEs) — 10; 10; 8; 3 Participants